Tags

Type your tag names separated by a space and hit enter

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.
Science. 2021 Mar 25 [Online ahead of print]Sci

Abstract

Emerging SARS-CoV-2 variants have raised concerns about resistance to neutralizing antibodies elicited by previous infection or vaccination. We examined whether sera from recovered and naïve donors collected prior to, and following immunizations with existing mRNA vaccines, could neutralize the Wuhan-Hu-1 and B.1.351 variants. Pre-vaccination sera from recovered donors neutralized Wuhan-Hu-1 and sporadically neutralized B.1.351, but a single immunization boosted neutralizing titers against all variants and SARS-CoV-1 by up to 1000-fold. Neutralization was due to antibodies targeting the receptor binding domain and was not boosted by a second immunization. Immunization of naïve donors also elicited cross-neutralizing responses, but at lower titers. Our study highlights the importance of vaccinating both uninfected and previously infected persons to elicit cross-variant neutralizing antibodies.

Authors+Show Affiliations

Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA. amcguire@fredhutch.org lstamata@fredhutch.org jmcelrat@fredhutch.org. Department of Global Health, University of Washington, Seattle, WA, USA.Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.Centre de Recherche du CHUM, Montréal, QC, Canada. Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada. Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada.Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA. amcguire@fredhutch.org lstamata@fredhutch.org jmcelrat@fredhutch.org. Department of Global Health, University of Washington, Seattle, WA, USA. Department of Medicine, University of Washington, Seattle, WA, USA.Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA. amcguire@fredhutch.org lstamata@fredhutch.org jmcelrat@fredhutch.org. Department of Global Health, University of Washington, Seattle, WA, USA. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.

Pub Type(s)

Editorial

Language

eng

PubMed ID

33766944

Citation

Stamatatos, Leonidas, et al. "MRNA Vaccination Boosts Cross-variant Neutralizing Antibodies Elicited By SARS-CoV-2 Infection." Science (New York, N.Y.), 2021.
Stamatatos L, Czartoski J, Wan YH, et al. MRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021.
Stamatatos, L., Czartoski, J., Wan, Y. H., Homad, L. J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M. F., MacCamy, A. J., Feng, J., Mize, G., De Rosa, S. C., Finzi, A., Lemos, M. P., Cohen, K. W., Moodie, Z., McElrath, M. J., & McGuire, A. T. (2021). MRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science (New York, N.Y.). https://doi.org/10.1126/science.abg9175
Stamatatos L, et al. MRNA Vaccination Boosts Cross-variant Neutralizing Antibodies Elicited By SARS-CoV-2 Infection. Science. 2021 Mar 25; PubMed PMID: 33766944.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. AU - Stamatatos,Leonidas, AU - Czartoski,Julie, AU - Wan,Yu-Hsin, AU - Homad,Leah J, AU - Rubin,Vanessa, AU - Glantz,Hayley, AU - Neradilek,Moni, AU - Seydoux,Emilie, AU - Jennewein,Madeleine F, AU - MacCamy,Anna J, AU - Feng,Junli, AU - Mize,Gregory, AU - De Rosa,Stephen C, AU - Finzi,Andrés, AU - Lemos,Maria P, AU - Cohen,Kristen W, AU - Moodie,Zoe, AU - McElrath,M Juliana, AU - McGuire,Andrew T, Y1 - 2021/03/25/ PY - 2021/02/04/received PY - 2021/03/19/accepted PY - 2021/3/27/pubmed PY - 2021/3/27/medline PY - 2021/3/26/entrez JF - Science (New York, N.Y.) JO - Science N2 - Emerging SARS-CoV-2 variants have raised concerns about resistance to neutralizing antibodies elicited by previous infection or vaccination. We examined whether sera from recovered and naïve donors collected prior to, and following immunizations with existing mRNA vaccines, could neutralize the Wuhan-Hu-1 and B.1.351 variants. Pre-vaccination sera from recovered donors neutralized Wuhan-Hu-1 and sporadically neutralized B.1.351, but a single immunization boosted neutralizing titers against all variants and SARS-CoV-1 by up to 1000-fold. Neutralization was due to antibodies targeting the receptor binding domain and was not boosted by a second immunization. Immunization of naïve donors also elicited cross-neutralizing responses, but at lower titers. Our study highlights the importance of vaccinating both uninfected and previously infected persons to elicit cross-variant neutralizing antibodies. SN - 1095-9203 UR - https://www.unboundmedicine.com/medline/citation/33766944/full_citation L2 - https://www.sciencemag.org/cgi/pmidlookup?view=long&pmid=33766944 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.